Search

Your search keyword '"Rudà, Roberta"' showing total 849 results
Start Over Author "Rudà, Roberta"
849 results on '"Rudà, Roberta"'

101. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults

Author

Weller, Michael; https://orcid.org/0000-0002-1748-174X, Le Rhun, Émilie; https://orcid.org/0000-0002-9408-3278, Van den Bent, Martin, Chang, Susan M, Cloughesy, Timothy F, Goldbrunner, Roland, Hong, Yong-Kil, Jalali, Rakesh, Jenkinson, Michael D, Minniti, Giuseppe, Nagane, Motoo; https://orcid.org/0000-0002-0018-1652, Razis, Evangelia, Roth, Patrick, Rudà, Roberta, Tabatabai, Ghazaleh; https://orcid.org/0000-0002-3542-8782, Wen, Patrick Y, Short, Susan C, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Le Rhun, Émilie; https://orcid.org/0000-0002-9408-3278, Van den Bent, Martin, Chang, Susan M, Cloughesy, Timothy F, Goldbrunner, Roland, Hong, Yong-Kil, Jalali, Rakesh, Jenkinson, Michael D, Minniti, Giuseppe, Nagane, Motoo; https://orcid.org/0000-0002-0018-1652, Razis, Evangelia, Roth, Patrick, Rudà, Roberta, Tabatabai, Ghazaleh; https://orcid.org/0000-0002-3542-8782, Wen, Patrick Y, Short, Susan C, and Preusser, Matthias; https://orcid.org/0000-0003-3541-2315

Abstract

Central nervous system (CNS) tumor patients commonly undergo multimodality treatment in the course of their disease. Adverse effects and complications from these interventions have not been systematically studied, but pose significant challenges in clinical practice and impact function and quality of life, especially in the management of long-term brain tumor survivors. Here, the European Association of Neuro-Oncology (EANO) has developed recommendations to prevent, diagnose, and manage adverse effects and complications in the adult primary brain CNS tumor (except lymphomas) patient population with a specific focus on surgery, radiotherapy, and pharmacotherapy. Specifically, we also provide recommendations for dose adaptations, interruptions, and reexposure for pharmacotherapy that may serve as a reference for the management of standard of care in clinical trials. We also summarize which interventions are unnecessary, inactive or contraindicated. This consensus paper should serve as a reference for the conduct of standard therapy within and outside of clinical trials.

Published
2023

102. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)

Author

Hertler, Caroline; https://orcid.org/0000-0001-6181-2895, Felsberg, Jörg, Gramatzki, Dorothee; https://orcid.org/0000-0002-9054-5498, Le Rhun, Emilie; https://orcid.org/0000-0002-9408-3278, Clarke, Jennifer; https://orcid.org/0000-0002-8054-7342, Soffietti, Riccardo; https://orcid.org/0000-0002-9204-7038, Wick, Wolfgang, Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F, Reijneveld, Jaap, Schnell, Oliver; https://orcid.org/0000-0002-1284-1427, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A, van den Bent, Martin; https://orcid.org/0000-0001-5710-5127, Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F, Phillips, Samuel, Rudà, Roberta, Wick, Antje, et al, Rushing, Elisabeth; https://orcid.org/0000-0001-7616-6320, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Hertler, Caroline; https://orcid.org/0000-0001-6181-2895, Felsberg, Jörg, Gramatzki, Dorothee; https://orcid.org/0000-0002-9054-5498, Le Rhun, Emilie; https://orcid.org/0000-0002-9408-3278, Clarke, Jennifer; https://orcid.org/0000-0002-8054-7342, Soffietti, Riccardo; https://orcid.org/0000-0002-9204-7038, Wick, Wolfgang, Chinot, Olivier, Ducray, François, Roth, Patrick, McDonald, Kerrie, Hau, Peter, Hottinger, Andreas F, Reijneveld, Jaap, Schnell, Oliver; https://orcid.org/0000-0002-1284-1427, Marosi, Christine, Glantz, Michael, Darlix, Amélie, Lombardi, Giuseppe, Krex, Dietmar, Glas, Martin, Reardon, David A, van den Bent, Martin; https://orcid.org/0000-0001-5710-5127, Lefranc, Florence, Herrlinger, Ulrich, Razis, Evangelia, Carpentier, Antoine F, Phillips, Samuel, Rudà, Roberta, Wick, Antje, et al, Rushing, Elisabeth; https://orcid.org/0000-0001-7616-6320, and Weller, Michael; https://orcid.org/0000-0002-1748-174X

Abstract

Background: Median survival with glioblastoma remains in the range of 12 months on population levels. Only few patients survive for more than 5 years. Patient and disease features associated with long-term survival remain poorly defined. Methods: European Organization for Research and Treatment of Cancer (EORTC) 1419 (ETERNITY) is a registry study supported by the Brain Tumor Funders Collaborative in the US and the EORTC Brain Tumor Group. Patients with glioblastoma surviving at least 5 years from diagnosis were identified at 24 sites in Europe, US, and Australia. In patients with isocitrate dehydrogenase (IDH) wildtype tumours, prognostic factors were analysed using the Kaplan-Meier method and the Cox proportional hazards model. A population-based reference cohort was obtained from the Cantonal cancer registry Zurich. Results: At the database lock of July 2020, 280 patients with histologically centrally confirmed glioblastoma (189 IDH wildtype, 80 IDH mutant, 11 incompletely characterised) had been registered. In the IDH wildtype population, median age was 56 years (range 24-78 years), 96 patients (50.8%) were female, 139 patients (74.3%) had tumours with O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. Median overall survival was 9.9 years (95% confidence interval [95% CI] 7.9-11.9). Patients without recurrence experienced longer median survival (not reached) than patients with one or more recurrences (8.92 years) (p < 0.001) and had a high rate (48.8%) of MGMT promoter-unmethylated tumours. Conclusions: Freedom from progression is a powerful predictor of overall survival in long-term survivors with glioblastoma. Patients without relapse often have MGMT promoter-unmethylated glioblastoma and may represent a distinct subtype of glioblastoma.

Published
2023

103. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection

Author

Capper, David; https://orcid.org/0000-0003-1945-497X, Reifenberger, Guido, French, Pim J, Schweizer, Leonille; https://orcid.org/0000-0002-4649-2587, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Touat, Mehdi, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Euskirchen, Philipp; https://orcid.org/0000-0002-9138-805X, Haberler, Christine; https://orcid.org/0000-0003-1016-0545, Hegi, Monika E, Brandner, Sebastian; https://orcid.org/0000-0002-9821-0342, Le Rhun, Émilie; https://orcid.org/0000-0002-9408-3278, Rudà, Roberta, Sanson, Marc, Tabatabai, Ghazaleh; https://orcid.org/0000-0002-3542-8782, Sahm, Felix; https://orcid.org/0000-0001-5441-1962, Wen, Patrick Y, Wesseling, Pieter, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, van den Bent, Martin J; https://orcid.org/0000-0001-5710-5127, Capper, David; https://orcid.org/0000-0003-1945-497X, Reifenberger, Guido, French, Pim J, Schweizer, Leonille; https://orcid.org/0000-0002-4649-2587, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Touat, Mehdi, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Euskirchen, Philipp; https://orcid.org/0000-0002-9138-805X, Haberler, Christine; https://orcid.org/0000-0003-1016-0545, Hegi, Monika E, Brandner, Sebastian; https://orcid.org/0000-0002-9821-0342, Le Rhun, Émilie; https://orcid.org/0000-0002-9408-3278, Rudà, Roberta, Sanson, Marc, Tabatabai, Ghazaleh; https://orcid.org/0000-0002-3542-8782, Sahm, Felix; https://orcid.org/0000-0001-5441-1962, Wen, Patrick Y, Wesseling, Pieter, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, and van den Bent, Martin J; https://orcid.org/0000-0001-5710-5127

Abstract

The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied. Despite that, there is increasing use of advanced molecular diagnostics that identify potential targets, and tumor-agnostic regulatory approvals on targets also present in CNS tumors have been granted. This raises the question of when and for which targets it is meaningful to test in adult patients with CNS tumors. This evidence-based guideline reviews the evidence available for targeted treatment for alterations in the RAS/MAPK pathway (BRAF, NF1), in growth factor receptors (EGFR, ALK, fibroblast growth factor receptor (FGFR), neurotrophic tyrosine receptor kinase (NTRK), platelet-derived growth factor receptor alpha, and ROS1), in cell cycle signaling (CDK4/6, MDM2/4, and TSC1/2) and altered genomic stability (mismatch repair, POLE, high tumor mutational burden (TMB), homologous recombination deficiency) in adult patients with gliomas, glioneuronal and neuronal tumors. At present, targeted treatment for BRAF p.V600E alterations is to be considered part of the standard of care for patients with recurrent gliomas, pending regulatory approval. For approved tumor agnostic treatments for NTRK fusions and high TMB, the evidence for efficacy in adult patients with CNS tumors is very limited, and treatment should preferably be given within prospective clinical registries and trials. For targeted treatment of CNS tumors with FGFR fusions or mutations, clinical trials are ongoing to confirm modest activity so far observed in basket trials. For all other reviewed targets, evidence of benefit in CNS tumors is currently lacking, and testing/treatment should be in the context of available clinical trials.

Published
2023

104. Gender balance and suitable positive actions to promote gender equality among healthcare professionals in neuro-oncology: The EANO positive action initiative.

Author

Rhun, Emilie Le, Boele, Florien, Minniti, Giuseppe, Galldiks, Norbert, Taphoorn, Martin, Piil, Karin, Rudà, Roberta, Niclou, Simone P, Geurts, Marjolein, Preusser, Matthias, Weller, Michael, Short, Susan C, and Dirven, Linda

Subjects
GENDER inequality, MEDICAL personnel, OVERTIME pay, WORK-life balance, MEDICAL research
Abstract

Background The proportion of women among healthcare and biomedical research professionals in neuro-oncology is growing. With changes in cultural expectations and work-life balance considerations, more men aspire to nonfull-time jobs, yet, leadership positions remain dominated by men. Methods The European Association of Neuro-Oncology (EANO) disparity committee carried out a digital survey to explore gender balance and actions suitable to promote gender equality. The survey was distributed among EANO members in 2021, with responses analyzed descriptively. Results In total, 262 participants completed the survey (141 women, 53.8%; median age 43). Respondents were neurosurgeons (68, 26.0%); neurologists (67, 25.6%), medical oncologists (43, 16.4%), or other healthcare or research professionals; 208 participants (79.4%) worked full-time. Positive action to enforce the role of women in neuro-oncology was deemed necessary by 180 participants (68.7%), but only 28 participants (10.7%) agreed that women only should be promoted until gender balance is reached. A majority of respondents (162, 61.8%) felt that women with an equivalent CV should be prioritized over men to reach gender balance. If in the future the balance favored women at higher positions, 112 respondents (42.7%) agreed to apply positive action for men. The top indicators considered relevant to measure gender balance were: salary for similar positions (183/228, 80.3%), paid overtime (176/228, 77.2%), number of permanent positions (164/228, 71.9%), protected time for research (161/227, 70.9%), and training opportunities (157/227, 69.2%). Conclusions Specific indicators may help to measure and promote gender balance and should be considered for implementation among healthcare professionals in neuro-oncology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

105. The early recognition and diagnosis of neoplastic meningitis.

Author

Pellerino, Alessia, Bertero, Luca, Pronello, Edoardo, Rudà, Roberta, and Soffietti, Riccardo

Abstract

The diagnosis and monitoring of leptomeningeal metastases (LM) from solid tumors are challenging, and the combination of neurological symptoms, MRI findings, and cerebrospinal fluid (CSF) cytology does not always allow to achieve a definitive diagnosis. This review summarizes the studies that have investigated CSF liquid biopsy to improve the initial diagnosis of LM in case the CSF cytology is negative or only suspicious for tumor cells, and monitoring of tumor response following targeted therapies or immunotherapy. In this regard, the early detection of LM recurrence and the development of resistant mutations are critical issues. Moreover, the early identification of subgroups of patients with a higher risk of LM progression, as well as the correlation of LM burden with survival, are discussed. There is an urgent need of prospective studies to monitor longitudinally LM using CSF liquid biopsy and investigate the role of CTC, ctDNA or novel assays. The optimal setting for the longitudinal CSF and blood collection can be clinical trials focused on the molecular diagnosis of LM as well as the response and monitoring following targeted agents. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

107. Advances in molecular and imaging biomarkers in lower-grade gliomas.

Author

Picca, Alberto, Bruno, Francesco, Nichelli, Lucia, Sanson, Marc, and Rudà, Roberta

Abstract

Lower-grade (grade 2–3) gliomas (LGGs) constitutes a group of primary brain tumors with variable clinical behaviors and treatment responses. Recent advancements in molecular biology have redefined their classification, and novel imaging modalities emerged for the noninvasive diagnosis and follow-up. This review comprehensively analyses the current knowledge on molecular and imaging biomarkers in LGGs. Key molecular alterations, such as IDH mutations and 1p/19q codeletion, are discussed for their prognostic and predictive implications in guiding treatment decisions. Moreover, the authors explore theranostic biomarkers for the potential of tailored therapies. Additionally, they also describe the utility of advanced imaging modalities, including widely available techniques, as dynamic susceptibility contrast perfusion-weighted imaging and less validated, emerging approaches, for the noninvasive LGGs characterization and follow-up. The integration of molecular markers enhanced the stratification of LGGs, leading to the new concept of integrated histomolecular classification. While the IDH mutation is an established key prognostic and predictive marker, recent results from IDH inhibitors trials showed its potential value as a theranostic marker. In this setting, advanced MRI techniques such as 2-D-hydroxyglutarate spectroscopy are very promising for the noninvasive diagnosis and monitoring of LGGs. This progress offers exciting prospects for personalized medicine and improved treatment outcomes in LGGs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

108. 215 Extent of Resection in Glioblastoma: Prognostic Validation of a New Classification from the RANO Resect Group

Author

Karschnia, Philipp, primary, Young, Jacob, additional, Ostorga, Antonio Gabriel Dono, additional, Häni, Levin, additional, Sciortino, Tommaso, additional, Bruno, Francesco, additional, Jünger, Stephanie T., additional, Teske, Nico, additional, Morshed, Ramin A., additional, Haddad, Alexander F., additional, Zhang, Yalan, additional, Stöcklein, Sophia, additional, Weller, Michael, additional, Vogelbaum, Michael A., additional, Beck, Juergen, additional, Tandon, Nitin, additional, Hervey-Jumper, Shawn L., additional, Molinaro, Annette, additional, Rudà, Roberta, additional, Bello, Lorenzo, additional, Schnell, Oliver, additional, Esquenazi, Yoshua, additional, Ruge, Maximilian I., additional, Grau, Stefan J., additional, Berger, Mitchel, additional, Chang, Susan M., additional, van den Bent, Martin, additional, and Tonn, Joerg-Christian, additional

Published
2023
Full Text
View/download PDF

109. Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Author

Tesileanu, C. Mircea S., primary, Sanson, Marc, primary, Wick, Wolfgang, primary, Brandes, Alba A., primary, Clement, Paul M., primary, Erridge, Sara C., primary, Vogelbaum, Michael A., primary, Nowak, Anna K., primary, Baurain, Jean-Francois, primary, Mason, Warren P., primary, Wheeler, Helen, primary, Chinot, Olivier L., primary, Gill, Sanjeev, primary, Griffin, Matthew, primary, Rogers, Leland, primary, Taal, Walter, primary, Rudà, Roberta, primary, Weller, Michael, primary, McBain, Catherine, primary, van Linde, Myra E., primary, Aldape, Kenneth, primary, Jenkins, Robert B., primary, Kros, Johan M., primary, Wesseling, Pieter, primary, von Deimling, Andreas, primary, Hoogstrate, Youri, primary, de Heer, Iris, primary, Atmodimedjo, Peggy N., primary, Dubbink, Hendrikus J., primary, Brouwer, Rutger W.W., primary, van IJcken, Wilfred F.J., primary, Cheung, Kin Jip, primary, Golfinopoulos, Vassilis, primary, Baumert, Brigitta G., primary, Gorlia, Thierry, primary, French, Pim J., primary, and van den Bent, Martin J., primary

Published
2023
Full Text
View/download PDF

110. Table S2 from Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis

Author

Indraccolo, Stefano, primary, De Salvo, Gian Luca, primary, Verza, Martina, primary, Caccese, Mario, primary, Esposito, Giovanni, primary, Piga, Ilaria, primary, Del Bianco, Paola, primary, Pizzi, Marco, primary, Gardiman, Marina Paola, primary, Eoli, Marica, primary, Rudà, Roberta, primary, Brandes, Alba Ariela, primary, Ibrahim, Toni, primary, Rizzato, Simona, primary, Lolli, Ivan, primary, Zagonel, Vittorina, primary, and Lombardi, Giuseppe, primary

Published
2023
Full Text
View/download PDF

111. Figure S3 from Phosphorylated Acetyl-CoA Carboxylase Is Associated with Clinical Benefit with Regorafenib in Relapsed Glioblastoma: REGOMA Trial Biomarker Analysis

Author

Indraccolo, Stefano, primary, De Salvo, Gian Luca, primary, Verza, Martina, primary, Caccese, Mario, primary, Esposito, Giovanni, primary, Piga, Ilaria, primary, Del Bianco, Paola, primary, Pizzi, Marco, primary, Gardiman, Marina Paola, primary, Eoli, Marica, primary, Rudà, Roberta, primary, Brandes, Alba Ariela, primary, Ibrahim, Toni, primary, Rizzato, Simona, primary, Lolli, Ivan, primary, Zagonel, Vittorina, primary, and Lombardi, Giuseppe, primary

Published
2023
Full Text
View/download PDF

112. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology

Author

Hoang-Xuan, Khê, Bessell, Eric, Bromberg, Jacoline, Hottinger, Andreas F, Preusser, Matthias, Rudà, Roberta, Schlegel, Uwe, Siegal, Tali, Soussain, Carole, Abacioglu, Ufuk, Cassoux, Nathalie, Deckert, Martina, Dirven, Clemens M F, Ferreri, Andrés J M, Graus, Francesc, Henriksson, Roger, Herrlinger, Ulrich, Taphoorn, Martin, Soffietti, Riccardo, and Weller, Michael

Published
2015
Full Text
View/download PDF

114. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma

Author

Lopci, Egesta, Riva, Marco, Olivari, Laura, Raneri, Fabio, Soffietti, Riccardo, Piccardo, Arnoldo, Bizzi, Alberto, Navarria, Pierina, Ascolese, Anna Maria, Rudà, Roberta, Fernandes, Bethania, Pessina, Federico, Grimaldi, Marco, Simonelli, Matteo, Rossi, Marco, Alfieri, Tommaso, Zucali, Paolo Andrea, Scorsetti, Marta, Bello, Lorenzo, and Chiti, Arturo

Published
2017
Full Text
View/download PDF

117. Ependymomas

Author

Gilbert, Mark R., Ruda, Roberta, Soffietti, Riccardo, Norden, Andrew D., editor, Reardon, David A., editor, and Wen, Patrick C. Y., editor

Published
2011
Full Text
View/download PDF

119. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection

Author

Capper, David, primary, Reifenberger, Guido, additional, French, Pim J, additional, Schweizer, Leonille, additional, Weller, Michael, additional, Touat, Mehdi, additional, Niclou, Simone P, additional, Euskirchen, Philipp, additional, Haberler, Christine, additional, Hegi, Monika E, additional, Brandner, Sebastian, additional, Le Rhun, Emilie, additional, Rudà, Roberta, additional, Sanson, Marc, additional, Tabatabai, Ghazaleh, additional, Sahm, Felix, additional, Wen, Patrick Y, additional, Wesseling, Pieter, additional, Preusser, Matthias, additional, and van den Bent, Martin J, additional

Published
2023
Full Text
View/download PDF

120. Deep Learning Based Algorithm For Postoperative Glioblastoma MRI Segmentation: A Promising New Tool For Tumor Burden Assessment

Author

Bonada, Marta, primary, Bianconi, Andrea, additional, Francesco Rossi, Luca, additional, Zeppa, Pietro, additional, Nico, Elsa, additional, De Marco, Raffaele, additional, Lacroce, Paola, additional, Cofano, Paolo, additional, Bruno, Francesco, additional, Melcarne, Antonio, additional, Morana, Giovanni, additional, Rudà, Roberta, additional, Mainardi, Luca, additional, Garbossa, Diego, additional, and Morra, Lia, additional

Published
2023
Full Text
View/download PDF

121. Evaluation Of Surgical Resection for Recurrent Glioblastoma Using The RANO Classification For Extent Of Resection: A Report Of The RANO Resect Group

Author

Karschnia, Philipp, primary, Dono, Antonio, additional, Young, Jacob S., additional, Jünger, Stephanie T., additional, Teske, Nico, additional, Häni, Levin, additional, Sciortino, Tommaso, additional, Mau, Christine Y., additional, Bruno, Francesco, additional, Weller, Michael, additional, Rudà, Roberta, additional, Vogelbaum, Michael A., additional, Bello, Lorenzo, additional, Schnell, Oliver, additional, Grau, Stefan J., additional, Chang, Susan M., additional, Berger, Mitchel S., additional, Esquenazi, Yoshua, additional, and Tonn, Joerg-Christian, additional

Published
2023
Full Text
View/download PDF

127. Ependymomas

Author

Rudà, Roberta, primary, Gilbert, Mark R., additional, and Soffietti, Riccardo, additional

Published
2017
Full Text
View/download PDF

135. SURG-19. PROGNOSTIC VALIDATION OF A NEW CLASSIFICATION SYSTEM FOR EXTENT OF RESECTION IN GLIOBLASTOMA: A REPORT OF THE RANO RESECT GROUP

Author

Karschnia, Philipp, primary, Young, Jacob S, additional, Dono, Antonio, additional, Häni, Levin, additional, Sciortino, Tommaso, additional, Bruno, Francesco, additional, Jünger, Stephanie T, additional, Teske, Nico, additional, Morshed, Ramin A, additional, Haddad, Alexander F, additional, Zhang, Yalan, additional, Stöcklein, Sophia, additional, Weller, Michael, additional, Vogelbaum, Michael, additional, Beck, Juergen, additional, Tandon, Nitin, additional, Hervey-Jumper, Shawn L, additional, Molinaro, Annette, additional, Rudà, Roberta, additional, Bello, Lorenzo, additional, Schnell, Oliver, additional, Esquenazi, Yoshua, additional, Ruge, Maximilian I, additional, Grau, Stefan J, additional, Berger, Mitchel S, additional, Chang, Susan M, additional, van den Bent, Martin, additional, and Tonn, Joerg-Christian, additional

Published
2022
Full Text
View/download PDF

137. Observational Real-Life Study on Regorafenib in Recurrent Glioblastoma: Does Dose Reduction Reduce Toxicity While Maintaining the Efficacy?

Author

Rudà, Roberta, primary, Bruno, Francesco, additional, Pellerino, Alessia, additional, Pronello, Edoardo, additional, Palmiero, Rosa, additional, Bertero, Luca, additional, Crasto, Stefania, additional, Polo, Valentina, additional, Vitaliani, Roberta, additional, Trincia, Elena, additional, Internò, Valeria, additional, Porta, Camillo, additional, and Soffietti, Riccardo, additional

Published
2022
Full Text
View/download PDF

138. Linea guida per la terapia dei prolattinomi: Associazione Medici Endocrinologi (AME); Istituto Superiore di Sanità 2022; Associazione Italiana di Neuro-Oncologia (AINO); Associazione Italiana di Neuroradiologia Diagnostica e Interventistica (AINR); Associazione Italiana di Radioterapia e Oncologia Clinica (AIRO); Associazione Nazionale Italiana Patologie Ipofisarie (ANIPI); Società Italiana di Biochimica Clinica e Biologia Molecolare Clinica (SIBioc); Società Italiana di Endocrinologia (SIE); Società Italiana di Ginecologia e Ostetricia (SIGO); Società Italiana di Neurochirurgia (SINch)

Author

Cozzi, Renato, Auriemma, Renata Simona, De Menis, Ernesto, Esposito, Felice, Fattori, Lawrence, Ferrante, Emanuele, Iatì, Giuseppe, Mazzatenta, Diego, Poggi, Maurizio, Rudà, Roberta, and Tortora, Fabio

Published
2023
Full Text
View/download PDF

139. Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)

Author

Lombardi, Giuseppe, Pace, Andrea, Pasqualetti, Francesco, Rizzato, Simona, Faedi, Marina, Anghileri, Elena, Nicolotto, Elisa, Bazzoli, Elena, Bellu, Luisa, Villani, Veronica, Fabi, Alessandra, Ferrazza, Patrizia, Gurrieri, Lorena, Dall’Agata, Monia, Eoli, Marica, Della Puppa, Alessandro, Pambuku, Ardi, D’Avella, Domenico, Berti, Franco, Rudà, Roberta, and Zagonel, Vittorina

Published
2015
Full Text
View/download PDF

143. Correction to: Efficacy of initial temozolomide for high‑risk low grade gliomas in a phase II AINO (Italian Association for Neuro‑Oncology) study: a post‑hoc analysis within molecular subgroups of WHO 2016

Author

Rudà, Roberta, Pellerino, Alessia, Pace, Andrea, Carapella, Carmine Maria, Dealis, Cristina, Caroli, Manuela, Faedi, Marina, Bello, Lorenzo, Migliore, Enrica, Marchese, Giulia, Bertero, Luca, Cassoni, Paola, and Soffietti, Riccardo

Published
2019
Full Text
View/download PDF

144. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group

Author

Karschnia, Philipp, primary, Young, Jacob S, additional, Dono, Antonio, additional, Häni, Levin, additional, Sciortino, Tommaso, additional, Bruno, Francesco, additional, Juenger, Stephanie T, additional, Teske, Nico, additional, Morshed, Ramin A, additional, Haddad, Alexander F, additional, Zhang, Yalan, additional, Stoecklein, Sophia, additional, Weller, Michael, additional, Vogelbaum, Michael A, additional, Beck, Juergen, additional, Tandon, Nitin, additional, Hervey-Jumper, Shawn, additional, Molinaro, Annette M, additional, Rudà, Roberta, additional, Bello, Lorenzo, additional, Schnell, Oliver, additional, Esquenazi, Yoshua, additional, Ruge, Maximilian I, additional, Grau, Stefan J, additional, Berger, Mitchel S, additional, Chang, Susan M, additional, van den Bent, Martin, additional, and Tonn, Joerg-Christian, additional

Published
2022
Full Text
View/download PDF

145. Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

Author

Saaid, Ayoub, primary, Monticelli, Matteo, additional, Ricci, Alessia Andrea, additional, Orlando, Giulia, additional, Botta, Cristina, additional, Zeppa, Pietro, additional, Bianconi, Andrea, additional, Osella-Abate, Simona, additional, Bruno, Francesco, additional, Pellerino, Alessia, additional, Rudà, Roberta, additional, Cassoni, Paola, additional, Garbossa, Diego, additional, Cofano, Fabio, additional, and Bertero, Luca, additional

Published
2022
Full Text
View/download PDF

146. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

Author

Hoang-Xuan, Khê, primary, Deckert, Martina, additional, Ferreri, Andrés J M, additional, Furtner, Julia, additional, Gallego Perez-Larraya, Jaime, additional, Henriksson, Roger, additional, Hottinger, Andreas F, additional, Kasenda, Benjamin, additional, Lefranc, Florence, additional, Lossos, Alexander, additional, McBain, Catherine, additional, Preusser, Matthias, additional, Roth, Patrick, additional, Rudà, Roberta, additional, Schlegel, Uwe, additional, Soffietti, Riccardo, additional, Soussain, Carole, additional, Taphoorn, Martin J B, additional, Touitou, Valérie, additional, Weller, Michael, additional, and Bromberg, Jacoline E C, additional

Published
2022
Full Text
View/download PDF

150. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, Tesileanu, C Mircea S, Sanson, Marc, Wick, Wolfgang, Brandes, Alba A, Clement, Paul M, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean-Francois, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, van Linde, Myra E, Aldape, Kenneth, Jenkins, Robert B, Kros, Johan M, Wesseling, Pieter, von Deimling, Andreas, Hoogstrate, Youri, de Heer, Iris, Atmodimedjo, Peggy N, Dubbink, Hendrikus J, Brouwer, Rutger W W, van IJcken, Wilfred F J, Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G, Gorlia, Thierry, French, Pim J, van den Bent, Martin J, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale, Tesileanu, C Mircea S, Sanson, Marc, Wick, Wolfgang, Brandes, Alba A, Clement, Paul M, Erridge, Sara C, Vogelbaum, Michael A, Nowak, Anna K, Baurain, Jean-Francois, Mason, Warren P, Wheeler, Helen, Chinot, Olivier L, Gill, Sanjeev, Griffin, Matthew, Rogers, Leland, Taal, Walter, Rudà, Roberta, Weller, Michael, McBain, Catherine, van Linde, Myra E, Aldape, Kenneth, Jenkins, Robert B, Kros, Johan M, Wesseling, Pieter, von Deimling, Andreas, Hoogstrate, Youri, de Heer, Iris, Atmodimedjo, Peggy N, Dubbink, Hendrikus J, Brouwer, Rutger W W, van IJcken, Wilfred F J, Cheung, Kin Jip, Golfinopoulos, Vassilis, Baumert, Brigitta G, Gorlia, Thierry, French, Pim J, and van den Bent, Martin J

Abstract

In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase-wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82-1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61-1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results